At a glance
ClinicalIndex Comparison RecordN/ACompleted· 227 enrolled
Drug / intervention
Untreated Whole Blood +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria
In Brief
A clinical study evaluating Mirasol-treated Whole Blood and Untreated Whole Blood for Malaria. Completed, enrolled 227 participants across 1 site.
Detailed Summary
The trial will evaluate the efficacy of the Mirasol Pathogen Reduction Technology for Whole Blood to prevent Malaria transmission by transfusion of whole blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesGhana
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedApr 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedApr 21, 2014
Enrollment StartMar 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.2 years ago
Interventions
Mirasol-treated Whole Blooddevice
Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
Untreated Whole Bloodbiological
Transfusion with untreated fresh Whole Blood